Federal regulators say a new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug. The Food and Drug Administration approved Zepbound on Wednesday. The drug has been shown to help dieters lose about a quarter of their body weight, or 60 pounds.
FILE - A sign for Eli Lilly & Co. stands outside their corporate headquarters in Indianapolis on April 26, 2017. A new study finds that the medicine in the diabetes drug Mounjaro helped people with obesity or who are overweight lose at least a quarter of their body weight. A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday.
Touted by celebrities and on social media, semaglutide and tirzepatide drugs have already been in such demand that their manufacturers have struggled to keep up. Both have been listed on the FDA’s drug shortage site for months. All strengths of tirzepatide are currently listed as available, but a company spokesperson said that could vary by location and demand.
While experts lauded approval of Zepbound, they worried that it wouldn’t necessarily mean greater access to the drug, which has been prescribed “off-label” to help people pare pounds. Eli Lilly and Co. said the list price for will be about $1,000 a month, the same as Mounjaro. Medicare is prohibited from covering drugs specifically for weight loss.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA approves new version of diabetes drug Mounjaro for weight lossFederal regulators say a new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug
Consulte Mais informação »
Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.The drug, which will be sold as Zepbound as an anti-obesity treatment, had previously been cleared by the FDA for the treatment of Type 2 diabetes
Consulte Mais informação »
Federal Reserve's Michael Barr calls for a strong federal framework for stablecoinsThe Federal Reserve's Michael Barr called for a strong framework for stablecoins amid concerns about their reliance on the central bank.
Consulte Mais informação »
US FTC disputes listing for more than 100 patents in FDA Orange BookUS FTC disputes listing for more than 100 patents in FDA Orange Book
Consulte Mais informação »
FDA moves to pull carbadox, drug used by pork industry, citing human cancer riskThe manufacturer of the drug called carbadox claims the move is not 'based on solid science.'
Consulte Mais informação »
US FTC disputes over 100 medical patents listed with FDA including asthma inhalersThe U.S. Federal Trade Commission (FTC) on Tuesday said it sent letters to medical device companies and drugmakers including AbbVie (ABBV.N), AstraZeneca (AZN.L) and Teva (TEVA.TA) disputing the accuracy or relevance of 110 patents that could lead to delays in generic competition.
Consulte Mais informação »